Cargando…
Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways
Cachexia represents one of the primary complications of colorectal cancer due to its effects on depletion of muscle and fat. Evidence suggests that chemotherapeutic regimens, such as Folfiri, contribute to cachexia-related symptoms. The purpose of the present study was to investigate the cachexia si...
Autores principales: | Barreto, Rafael, Mandili, Giorgia, Witzmann, Frank A., Novelli, Francesco, Zimmers, Teresa A., Bonetto, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070123/ https://www.ncbi.nlm.nih.gov/pubmed/27807421 http://dx.doi.org/10.3389/fphys.2016.00472 |
Ejemplares similares
-
Differential Bone Loss in Mouse Models of Colon Cancer Cachexia
por: Bonetto, Andrea, et al.
Publicado: (2017) -
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs
por: Barreto, Rafael, et al.
Publicado: (2016) -
Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia
por: Pin, Fabrizio, et al.
Publicado: (2018) -
The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
por: Au, Ernie D., et al.
Publicado: (2017) -
Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity
por: Collins, Kelsey H., et al.
Publicado: (2018)